HPV-associated head and neck cancer: The basics of molecular and translational research;Humane Papillomaviren bei Kopf-Hals-Karzinomen: Molekulare und translationale Grundlagen

HNO

Volumn 59, Issue 9, 2011, Pages 885-892

  Wittekindt, C ^a   Wagner, S ^a   Klussmann J P ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Head and neck cancer; Human papillomavirus; Oropharyngeal cancer; p16INK4 protein; Prognostic marker

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER; VIRUS DNA;

ARTICLE; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; OROPHARYNX TUMOR; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TRANSLATIONAL RESEARCH; VIROLOGY; VIRUS LATENCY;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN PAPILLOMAVIRUS 16; HUMANS; OROPHARYNGEAL NEOPLASMS; OTORHINOLARYNGOLOGIC NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL; VIRUS LATENCY;

EID: 80052293463     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-011-2357-1     Document Type: Article

References (54)

1. Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363: 24-35.
2. Barker N, Clevers H (2006) Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 5: 997-1014.
3. Baselga J, Rischin D, Ranson M et al (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292-4302.
4. Beder LB, Gunduz M, Ouchida M et al (2003) Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest 83: 99-105.
5. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578.
6. Burtness B, Goldwasser MA, Flood W et al (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23: 8646-8654.
7. Carpenter G, Liao HJ (2009) Trafficking of receptor tyrosine kinases to the nucleus. Exp Cell Res 315: 1556-1566.
8. Cervigne NK, Reis PP, Machado J et al (2009) Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum Mol Genet 18: 4818-4829.
9. Chung CH, Ely K, Mcgavran L et al (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24: 4170-4176.
10. Cohen EE, Rosen F, Stadler WM et al (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980-1987.
11. Cuzick J, Szarewski A, Cubie H et al (2003) Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362: 1871-1876.
12. D'souza G, Kreimer AR, Viscidi R et al (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356: 1944-1956.
13. De Villiers EM, Fauquet C, Broker TR et al (2004) Classification of papillomaviruses. Virology 324: 17-27.
14. Dittmann K, Mayer C, Rodemann HP (2005) Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76: 157-161.
15. Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100: 261-269.
16. Gillison ML, Koch WM, Capone RB et al (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 709-720.
17. Grandis JR, Tweardy DJ (1993) Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53: 3579-3584.
18. Hampl M, Wentzensen N, Vinokurova S et al (2007) Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile. J Cancer Res Clin Oncol 133: 235-245.
19. He TC, Sparks AB, Rago C et al (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
20. Heselmeyer-Haddad K, Sommerfeld K, White NM et al (2005) Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol 166: 1229-1238.
21. Kim JS, Crooks H, Foxworth A et al (2002) Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. Mol Cancer Ther 1: 1355-1359.
22. Kim SH, Koo BS, Kang S et al (2007) HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer 120: 1418-1425.
23. Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8: 387-398.
24. Klussmann JP, Dinh S, Guntinas-Lichius O et al (2004) HPV-associated tonsillar cancer. An update. HNO 52: 208-218.
25. Klussmann JP, Gultekin E, Weissenborn SJ et al (2003) Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162: 747-753.
26. Klussmann JP, Mooren JJ, Lehnen M et al (2009) Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res 15: 1779-1786.
27. Klussmann JP, Preuss SF, Speel EJ (2009) Human papillomavirus and cancer of the oropharynx. Molecular interaction and clinical implications. HNO 57: 113-122.
28. Kreimer AR, Clifford GM, Boyle P et al (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14: 467-475.
29. Lajer CB, Nielsen FC, Friis-Hansen L et al (o J) Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study. Br J Cancer 104: 830-840.
30. Liu CJ, Kao SY, Tu HF et al (2010) Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis 16: 360-364.
31. Liu X, Jiang L, Wang A et al (2009) MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett 286: 217-222.
32. Liu X, Yu J, Jiang L et al (2009) MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics 6: 131-139.
33. Loning T, Ikenberg H, Becker J et al (1985) Analysis of oral papillomas, leukoplakias, and invasive carcinomas for human papillomavirus type related DNA. J Invest Dermatol 84: 417-420.
34. Mcgovern SL, Williams MD, Weber RS et al (2010) Three synchronous HPV-associated squamous cell carcinomas of Waldeyer's ring: case report and comparison with Slaughter's model of field cancerization. Head Neck 32: 1118-1124.
35. Oda K, Matsuoka Y, Funahashi A et al (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 1: 2005. 0010.
36. Park NJ, Zhou H, Elashoff D et al (2009) Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 15: 5473-5477.
37. Ragin CC, Taioli E (2007) Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 121: 1813-1820.
38. Rampias T, Boutati E, Pectasides E et al (o J) Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res 8: 433-443.
39. Reimers N, Kasper HU, Weissenborn SJ et al (2007) Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 120: 1731-1738.
40. Ritchie JM, Smith EM, Summersgill KF et al (2003) Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 104: 336-344.
41. Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6: 963-968.
42. Smeets SJ, Braakhuis BJ, Abbas S et al (2006) Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25: 2558-2564.
43. Smeets SJ, Hesselink AT, Speel EJ et al (2007) A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 121: 2465-2472.
44. Snijders PJ, Steenbergen RD, Heideman DA et al (2006) HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 208: 152-164.
45. Stenner M, Yosef B, Huebbers CU et al (o J) Nuclear translocation of beta-catenin and decreased expression of epithelial cadherin in human papillomavirus-positive tonsillar cancer: an early event in human papillomavirus-related tumour progression? Histopathology.
46. Temam S, Kawaguchi H, El-Naggar AK et al (2007) Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25: 2164-2170.
47. Veltman JA, van Weert I, Aubele M et al (2001) Specific steps in aneuploidization correlate with loss of heterozygosity of 9p21, 17p13 and 18q21 in the progression of pre-malignant laryngeal lesions. Int J Cancer 91: 193-199.
48. Wanner G, Mayer C, Kehlbach R et al (2008) Activation of protein kinase Cepsilon stimulates DNA-repair via epidermal growth factor receptor nuclear accumulation. Radiother Oncol 86: 383-390.
49. Wentzensen N, Vinokurova S, Von Knebel Doeberitz M (2004) Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 64: 3878-3884.
50. Wilting SM, Smeets SJ, Snijders PJ et al (2009) Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med Genomics 2: 32.
51. Wittekindt C, Gultekin E, Weissenborn SJ et al (2005) Expression of p16 protein is associated with human papillomavirus status in tonsillar carcinomas and has implications on survival. Adv Otorhinolaryngol 62: 72-80.
52. Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250.
53. Yu ZW, Zhong LP, Ji T et al (2010) MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 46: 317-322.
54. Zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350.